$MDT

Medtronic and the IRS failed to settle a dispute regarding transfer pricing of intangibles licensed to a Puerto Rican affiliate. The parties informed the U.S. court of the unsuccessful settlement attempt, according to the report.

Medtronic (MDT), Abbott Laboratories (ABT), and Johnson & Johnson (JNJ) have long dividend growth streaks. MDT yields 2.95%, ABT 2.46%, and JNJ 2.0%. MDT's Q1 revenue rose 13.7%, while ABT and JNJ are restructuring. All pay out ~50% of earnings, with strong free cash flow.

Medtronic (MDT) raised its quarterly dividend by 1.4% to $0.72 per share, extending its 49-year streak of increases. The company reported strong growth and completed the split of its diabetes unit. Medtronic's payout ratio is about 48% of expected earnings, with robust cash flow. Revenue rose 13.7% to $9.76 billion, driven by cardiac ablation solutions. The stock trades at 14x forward earnings with a 2.95% yield.

Electrophysiologists presented data on Medtronic’s PulseSelect and Affera systems at APHRS 2026. Choi reported 100% acute PVI success in 1,160 procedures with PulseSelect, while Jung noted 86% one-year freedom from arrhythmia recurrence. Kalman highlighted Affera’s efficiency, with 97% durable PVI. Mountantonakis shared Sphere-9’s noninferiority in persistent AF, with 73.8% one-year efficacy.

Costa Rica received $5.12B in foreign direct investment in 2025, with 54.8% from the U.S. Medical devices were the largest export. Key investors include Boston Scientific, Medtronic, Intel, and Bayer. The free-zone regime, offering tax incentives, attracted 66.4% of investments. The U.S. is the top trading and security partner, while China, the IMF, and the World Bank have narrower roles.

Medtronic, a medical device company based in Ireland, told the Irish Government that Ireland's new 15% tax rate disadvantages firms incorporated there, putting them at a competitive disadvantage compared to US peers. The company, which moved its tax domicile to Ireland a decade ago, attributes this to the US withdrawing from a global tax agreement. Medtronic's presence in Galway is significant for the local economy.

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

Medtronic reported $36.4B in FY2026 revenue, up 8.4%, driven by 88% growth in cardiac ablation solutions. The company's Hugo robotic surgery system and planned diabetes division spin-off (MiniMed) are long-term growth drivers. Medtronic has raised dividends for 49 consecutive years, with a 3.1% forward yield. Challenges include tariff pressures and potential growth slowdown. Analysts rate it a buy with a $103 target, 10% above current levels.

Medtronic (MDT) experienced $94.9 million in net ETF selling on Oct. 16, driven by IHI, JVAL, and KNG. Over the last 5 days, ETFs were net buyers on 2 days and net sellers on 3. MDT reported $37.54 billion in trailing-12-month revenue, with a 2.95% dividend yield and a 0.95% YTD decline.